Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib

Maxime Vanmechelen; Diether Lambrechts; Thomas Van Brussel; Annelies Verbiest; Gabrielle Couchy; Patrick Schöffski; Herlinde Dumez; Philip R. Debruyne; Evelyne Lerut; Jean Pascal Machiels; Vincent Richard; Maarten Albersen; Vincent Verschaeve; Stéphane Oudard; Arnaud Méjean; Pascal Wolter; Jessica Zucman-Rossi; Benoit Beuselinck

doi:10.1016/j.clgc.2018.11.002

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib

Maxime Vanmechelen
, Diether Lambrechts
, Thomas Van Brussel
, Annelies Verbiest
, Gabrielle Couchy
, Patrick Schöffski
, Herlinde Dumez
, Philip R. Debruyne
, Evelyne Lerut
, Jean Pascal Machiels
, Vincent Richard
, Maarten Albersen
, Vincent Verschaeve
, Stéphane Oudard
, Arnaud Méjean
, Pascal Wolter
, Jessica Zucman-Rossi
, Benoit Beuselinck^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

We describe a potential biomarker associated with progression-free survival and overall survival on sunitinib in metastatic clear-cell renal cell carcinoma. rs2981582 is a polymorphism in the fibroblast growth factor receptor 2. In our series of 154 patients treated with sunitinib, the TT-variant, present in 13% of the patients, was associated with shorter progression-free survival and overall survival.

Original language	English
Pages (from-to)	e235-e246
Journal	Clinical Genitourinary Cancer
Volume	17
Issue number	2
DOIs	https://doi.org/10.1016/j.clgc.2018.11.002
Publication status	Published - Apr 2019
Externally published	Yes

ASJC Scopus subject areas

Oncology
Urology

Keywords

Angiogenesis inhibitor
Biomarker
Outcome
Prognosis
Single nucleotide polymorphisms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clgc.2018.11.002

Fingerprint

Dive into the research topics of 'Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib'. Together they form a unique fingerprint.

Cite this

Vanmechelen, M., Lambrechts, D., Van Brussel, T., Verbiest, A., Couchy, G., Schöffski, P., Dumez, H., Debruyne, P. R., Lerut, E., Machiels, J. P., Richard, V., Albersen, M., Verschaeve, V., Oudard, S., Méjean, A., Wolter, P., Zucman-Rossi, J., & Beuselinck, B. (2019). Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 17(2), e235-e246. https://doi.org/10.1016/j.clgc.2018.11.002

@article{9b3f045b118b4a2c83652c287d2931d5,

title = "Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib",

abstract = "We describe a potential biomarker associated with progression-free survival and overall survival on sunitinib in metastatic clear-cell renal cell carcinoma. rs2981582 is a polymorphism in the fibroblast growth factor receptor 2. In our series of 154 patients treated with sunitinib, the TT-variant, present in 13\% of the patients, was associated with shorter progression-free survival and overall survival.",

keywords = "Angiogenesis inhibitor, Biomarker, Outcome, Prognosis, Single nucleotide polymorphisms",

author = "Maxime Vanmechelen and Diether Lambrechts and \{Van Brussel\}, Thomas and Annelies Verbiest and Gabrielle Couchy and Patrick Sch{\"o}ffski and Herlinde Dumez and Debruyne, \{Philip R.\} and Evelyne Lerut and Machiels, \{Jean Pascal\} and Vincent Richard and Maarten Albersen and Vincent Verschaeve and St{\'e}phane Oudard and Arnaud M{\'e}jean and Pascal Wolter and Jessica Zucman-Rossi and Benoit Beuselinck",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = apr,

doi = "10.1016/j.clgc.2018.11.002",

language = "English",

volume = "17",

pages = "e235--e246",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "2",

}

Vanmechelen, M, Lambrechts, D, Van Brussel, T, Verbiest, A, Couchy, G, Schöffski, P, Dumez, H, Debruyne, PR, Lerut, E, Machiels, JP, Richard, V, Albersen, M, Verschaeve, V, Oudard, S, Méjean, A, Wolter, P, Zucman-Rossi, J & Beuselinck, B 2019, 'Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib', Clinical Genitourinary Cancer, vol. 17, no. 2, pp. e235-e246. https://doi.org/10.1016/j.clgc.2018.11.002

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. / Vanmechelen, Maxime; Lambrechts, Diether; Van Brussel, Thomas et al.
In: Clinical Genitourinary Cancer, Vol. 17, No. 2, 04.2019, p. e235-e246.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib

AU - Vanmechelen, Maxime

AU - Lambrechts, Diether

AU - Van Brussel, Thomas

AU - Verbiest, Annelies

AU - Couchy, Gabrielle

AU - Schöffski, Patrick

AU - Dumez, Herlinde

AU - Debruyne, Philip R.

AU - Lerut, Evelyne

AU - Machiels, Jean Pascal

AU - Richard, Vincent

AU - Albersen, Maarten

AU - Verschaeve, Vincent

AU - Oudard, Stéphane

AU - Méjean, Arnaud

AU - Wolter, Pascal

AU - Zucman-Rossi, Jessica

AU - Beuselinck, Benoit

PY - 2019/4

Y1 - 2019/4

N2 - We describe a potential biomarker associated with progression-free survival and overall survival on sunitinib in metastatic clear-cell renal cell carcinoma. rs2981582 is a polymorphism in the fibroblast growth factor receptor 2. In our series of 154 patients treated with sunitinib, the TT-variant, present in 13% of the patients, was associated with shorter progression-free survival and overall survival.

AB - We describe a potential biomarker associated with progression-free survival and overall survival on sunitinib in metastatic clear-cell renal cell carcinoma. rs2981582 is a polymorphism in the fibroblast growth factor receptor 2. In our series of 154 patients treated with sunitinib, the TT-variant, present in 13% of the patients, was associated with shorter progression-free survival and overall survival.

KW - Angiogenesis inhibitor

KW - Biomarker

KW - Outcome

KW - Prognosis

KW - Single nucleotide polymorphisms

UR - https://www.scopus.com/pages/publications/85057855804

U2 - 10.1016/j.clgc.2018.11.002

DO - 10.1016/j.clgc.2018.11.002

M3 - Article

C2 - 30527746

AN - SCOPUS:85057855804

SN - 1558-7673

VL - 17

SP - e235-e246

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 2

ER -

Vanmechelen M, Lambrechts D, Van Brussel T, Verbiest A, Couchy G, Schöffski P et al. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer. 2019 Apr;17(2):e235-e246. doi: 10.1016/j.clgc.2018.11.002

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib

Abstract

ASJC Scopus subject areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this